A panel of six murine monoclonal antibodies against hepatocellular carcinoma-associated antigens, reactive with PLC/PRF/5 human hepatoma cells, was conjugated to Adriamycin (doxorubicin) via a dextran bridge. This library of antibodies includes three monoclonal antibodies against hepatitis B virus surface antigen, one anti-a-fetoprotein, and two other IgG2a antibodies against PLC/PRF/5 hepatomaassociated antigens. The use of dextran for conjugation of
[3H]thymidine incorporation assays in hepatoma cells as compared to nonconjugated Adriamycin. This loss of anticellular activity was partially compensated for by conjugation of specific antibodies to the dextran-Adriamycin conjugate. Conjugated compounds completely retained their binding activity to purified hepatitis B virus surface antigen and a-fetoprotein fixed to a solid matrix as compared to binding of homologous nonconjugated antibodies. However, some reduction of the binding activity to intact hepatoma cells was observed in three of six conjugates. Binding activity to hepatoma cells and, as a consequence, suppression of tumor cell DNA synthesis by the various conjugates was enhanced as compared to the same effect in treated colorectal carcinoma cells that do not express the relevant hepatoma-associated proteins. Furthermore, two conjugates containing nonspecific antibodies did not bind to hepatoma cells and caused minimal suppression of DNA synthesis. These results suggest that this panel of monoclonal antibody-dextran-Adriamycin conjugates was effective in suppression of PLC/PRF/5 cell growth in vitro.
Available chemotherapy for primary hepatocellular carcinoma (HCC) is not effective and usually produces only a partial remission. For example, Adriamycin (Adr; doxorubicin) is currently used for chemotherapy in HCC, leading to variable remission in 11-25% of patients (1) . Its use, however, is restricted because of toxicity to normal tissues. Specific targeting of Adr to tumor cells may reduce its systemic toxicity and improve treatment efficacy. Conjugation of chemotherapeutic agents to carrier molecules such as polyclonal or monoclonal (mAbs) antibodies has been suggested (2, 3) . We, and others, have previously reported the linking of such agents to antibodies either directly or via inert macromolecules through covalent binding of drug and antibody (3) (4) (5) (6) . In a previous study (7, 8) , we (9) . Antibodies were partially purified from ascitic fluid of mice injected with somatic cell hybrid clones, using ammonium sulfate precipitation (IgGl), affinity purification with protein A-Sepharose 4B (IgG2a), and AcA 34 (IgM) columns as described (9) .
Cell Lines. Human hepatoma cell lines PLC/PRF/5 (12), SK-Hepl (13), and Mahlavu (14) , as well as colorectal carcinoma cells SW948, used for control experiments, were grown in culture as monolayers with RPMI 1640 medium supplemented with 10% fetal bovine serum, L-glutamine, nonessential amino acids, and antibiotics, and cells were harvested by trypsin/EDTA as described (15) . PLC/PRF/5 and Mahlavu hepatoma cells contain integrated hepatitis B virus DNA, but only PLC/PRF/5 cells express and secrete HBsAg and AFP (15) . The three hepatoma cell lines express two hepatoma-associated antigens-HAA1 and HAA2-of70 and 50 kDa, respectively (10, 11) .
Conjugation of Adr to mAbs. Purified mAbs were coupled to oxidized Dex as described (3) . Briefly, 1 g of Dex T10 (10 kDa) (Pharmacia, Uppsala) was dissolved in 100 ml of 0.03 M NaIO4 in 0. tTo whom reprint requests should be addressed.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. continued for 48 hr at 40C. The conjugate mAb-Dex-Adr was then purified by separation on a Sephadex G150 or Bio-Gel P60 (Bio-Rad) column. The final preparations were passed through a 0.22-pum filter. Conjugation of Adr to mAb was performed at least three times for each antibody and 37 batches were prepared. All conjugates were tested for their binding activity to intact hepatoma cells. Those conjugates containing mAb anti-HBs and anti-AFP were also tested for their binding activity to purified HBsAg and AFP fixed to a solid matrix. Only conjugates that retained 60% or more of their binding activity as compared to nonconjugated homologous mAb were then evaluated in a [3H]thymidine incorporation assay. All experiments were repeated three times or more for each conjugate.
Determination of Antibody Binding Activity of the Conjugate. mAb binding activity of the various conjugates or their individual uncoupled antibodies to the target proteins was tested by a variety of direct and indirect assays as described (3, (9) (10) (11) 16) . Binding activity of the conjugates was also compared to binding of the uncoupled homologous mAb to PLC/PRF/5 cells. Specificity of binding was determined for each antibody by comparing the binding of 125I-labeled mAb to its target before and after addition of nonlabeled homologous antibody or conjugate at a 10 to 100-fold excess (10) . Finally, once direct binding activity and specificity for each conjugate were determined, a comparative indirect binding assay was performed simultaneously for all six conjugates and controls (11) . Table 3 and Fig. 3 ), inhibition of thymidine incorporation was calculated according to the following formula: A = (B -C)/(B x 100), where A represents net percentage inhibition of thymidine incorporation by conjugate, B is the incorporation of thymidine in the presence of nonconjugated homologous mAb (dpm), and C is incorporation in the presence of conjugate (dpm). Conjugates containing mAb anti-HBs, anti-PLC1, anti-PLC2, and anti-AFP were significantly more inhibitory as compared to conjugates containing nonrelevant control antibodies such as anti-influenza-Dex-Adr (Table 1; Figs. 2 and 3) . Moreover, the effect of relevant antibodies containing conjugates was more pronounced against hepatoma cells as compared to the effect on colorectal carcinoma cells (Table 1) . Finally, conjugates containing mAbs anti-PLC1 and anti-PLC2 were also effective against PLC/PRF/5, as well as against SKHepl. and Mahlavu hepatoma cells ( Table 2) . The pharmacologic activity in vitro of the conjugates may vary between batches using the same antibody as well as between conjugates containing different mAbs because of a varying degree of drug substitution (range, 20-50 mol of drug per mol of mAb). In Table. 3, the relative efficacy of the individual conjugates is compared under partially defined conditions. These results indicate that specific conjugates were superior to nonspecific conjugates as well as to Dex-Adr in inhibition of thymidine incorporation into hepatoma cells. Finally, among this panel of six immunoconjugates tested in vitro, compounds containing anti-HBs mAbs of all three isotypes were the most potent inhibitors of cellular DNA synthesis, while the conjugate containing anti-AFP mAb was shown to be the least effective.
DISCUSSION
The generation of mAbs to tumor-associated antigens has enabled the development of a wide range of potential applications such as serologic and pathologic diagnosis, radioimmunolocalization, and immunotherapy (4) (5) (6) 17) . We have recently established a panel of mAbs reactive with human hepatoma-associated antigens (9, 10). One of these antigens is membrane associated (HAA2), while others are secreted in various amounts by. different hepatoma cells (HBsAg, HAA1, AFP). All these antigens are expressed by a human hepatoma cell line, PLC/PRF/5, and their respective ahtibodies bind specifically to these cells. We used this model system in vitro to assess the option of immunochemotherapy. In previous experiments, it was shown that treatment of PLC/PRF/5 PLC/PRF/5 hepatoma or SW948 colorectal cells were incubated with conjugates or their individual components for 4 hr at 3P7C, washed, and incubated with [3H]thymidine as described (10) Conditions were as described in Fig. 2 . Adr concentration was 2
,ug/ml and mAb concentration was for anti-PLC,, 1.25 /ug/ml; anti-PLC2, 0.6 tug/ml; anti-AFP, 6 ,ug/ml. NT, not tested.
*P < 0.01; **P < 0.05 as compared to Dex-Adr.
tumor-injected athymic mice with nonconjugated monoclonal anti-HBs (IgG2a or IgM) provided a protective effect against tumor formation. However, in some instances, treatment had led to "escape" tumors that were 3-fold larger than tumors in untreated animals (17) (18) (19) . To prevent such an escape phenomenon, several options are now being explored as shown in the present investigation. These include generation of additional mAbs to hepatoma-associated antigens, which may be administered sequentially or in combinations (10, 11) and the construction ofconjugates between the above antibodies and Adr. Adr is one ofthe few available chemotherapeutic agents for HCC, but its use is mainly restricted because of its cardiac and bone marrow toxicity. Treatment with mAbs conjugated with Adr should theoretically increase the drug concentration at the tumor site while reducing its systemic side effects. Conjugation of Adr to polyclonal antibodies or to mAbs via a Dex bridge has been reported (3) and Dex has been used in humans as an inert, soluble, and nontoxic volume expander. The use of Dex leads to a 10-to 50-fold amplification of the number of Adr molecules coupled to antibody. Although the controlled oxidation of Dex enables the conjugation of drug and antibody, batch to batch variation among conjugates may fluctuate between 10% and 30% in terms of drug substitution, even under optimal conditions. The conjugation process of Dex to drug or antibody depends on the available free aldehyde groups on the oxidized spacer. These aldehyde groups are then bound to functional free amino groups ofdrug and of antibody through the formation of Schiff bases. Three ofthe six conjugates reported in the present study maintained their binding activity to the target cells as compared to nonconjugated homologous mAbs, while in the remaining three conjugates a reduction in the binding activity was observed. Nevertheless, this loss in binding activity was not present for binding of anti-HBs-Dex-Adr to purified HBsAg thymidine incorporation assay. This loss of pharmacologic activity of Dex-Adr as compared to free Adr was partially compensated for by conjugation of the specific antibodies. Full compensation was achieved when incubation time between conjugate and target cells was extended from 4 to 16 hr. Despite the loss in binding activity after the conjugation process, conjugates containing specific mAbs were always significantly more potent as compared to Dex-Adr or to conjugates containing nonspecific mAbs that do not bind to the target cells. Such a synergistic effect between mAb and DexAdr was previously observed in experiments in which antiHBs Dex-Adr was more cytotoxic to hepatoma cells as compared to the effect of free Adr in a 51Cr release assay (16) . The strategy of using conjugates may have some more limitations in view of the fact that some nonconjugated mAbs caused stimulation of thymidine incorporation in hepatoma cells. Furthermore, PLC/PRF/5 hepatoma cells secrete HBsAg and AFP, which could interfere with the binding of their specific mAbs to the target by the formation of immune complexes. It was therefore surprising to observe that conjugates containing monoclonal anti-HBs, regardless of isotype used, were the most potent inhibitors ofDNA synthesis among the conjugates tested. These results support previous observations in which treatment of athymic mice with nonconjugated mAb anti-HBs (IgG2a and IgM) lead to an impressive protection against s.c. PLC/PRF/5 tumor growth in 75% of treated athymic mice, despite the presence of circulating HBsAg (17, 18) . In contrast, conjugates containing mAb anti-AFP were the least effective in the present study, despite their preserved binding activity to the target cells, as reflected by the relatively large concentration of Adr necessary to produce a 50% inhibition of thymidine incorporation in vitro.
The mechanism(s) by which conjugates cause injury to hepatoma cells has not been established yet. In preliminary experiments, there is some evidence that conjugates may react with the hepatoma cell membrane in a manner independent from the complement-mediated injury reported previously for mAbs anti-HBs IgG2a and IgM (9) . It is unknown whether conjugates are internalized intact or disperse into their individual components upon contact with the cell surface, and further studies are required.
In summary, we have shown that conjugates between mAbs to hepatoma-associated antigens and Adr are highly effective in vitro in causing specific target cell injury. 
